Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.49 |
| ▸ | QDPR | P09417 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | KHK | P50053 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2278255 | 0.99 | HTR2C (0.50) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL20395786 | 0.99 | HTR2C (0.50) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL12374234 | 0.87 | HTR2C (0.39) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL2275244 | 0.86 | HTR2C (0.40) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL18113566 | 0.84 | ALOX5AP (0.44) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL20414655 | 0.84 | ALOX5AP (0.44) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL20420134 | 0.84 | HTR2C (0.43) | HTR2CQDPRSIGMAR1KHK | |
| Hydrochloric Acid SCHEMBL18113568 | 0.83 | HTR2C (0.44) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL2278717 | 0.82 | HTR2C (0.45) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL2275039 | 0.82 | HTR2C (0.49) | HTR2CQDPRSIGMAR1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2021-04-22 | — | — | US | disclosed |
| US-10934304-B2 | Spirocyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| CN-107849053-B | Spiro compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2020-07-02 | — | — | US | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018067512-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-3277690-A1 | SPIROCYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885QDPR 2060/4885SIGMAR1 2013/4885 |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885QDPR 2060/4885SIGMAR1 2013/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885QDPR 2060/4885SIGMAR1 2013/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | HTR2C 3854/4885QDPR 598/4885SIGMAR1 1297/4885 |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885QDPR 2060/4885SIGMAR1 2013/4885 |
| US-10934304-B2 | Spirocyclic compounds | PKD1, AR, PKD2 | HTR2C 2823/4885QDPR 2060/4885SIGMAR1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.